- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04770220
Une étude d'efficacité et d'innocuité de l'ALZ-801 chez les sujets AD précoces APOE4/4 (APOLLOE4)
Une étude de phase 3, multicentrique, randomisée, en double aveugle et contrôlée par placebo sur l'efficacité, l'innocuité et les effets des biomarqueurs de l'ALZ-801 chez des sujets atteints de la maladie d'Alzheimer au stade précoce et du génotype APOE4/4
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Aachen, Allemagne, 52074
- University Hospital RWTH Aachen Neurological Study Center
-
München, Allemagne, 80336
- Klinikum der Universitaet Muenchen Innenstadt
-
Tübingen, Allemagne, 72076
- Universitätsklinik fuer Psychiatrie und Psychotherapie
-
Westerstede, Allemagne, 26655
- Studienzentrum Nord-West
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3S 1N2
- Centricity Research
-
New Minas, Nova Scotia, Canada, B4N 3R7
- Centricity Research
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Z 1G3
- Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
-
Peterborough, Ontario, Canada, K9H 2P4
- Kawartha Centre - Redefining Healthy Aging
-
Toronto, Ontario, Canada, M3B 2S7
- Toronto Memory Program
-
-
Quebec
-
Gatineau, Quebec, Canada, J8T 8J1
- Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
-
-
-
-
-
Barcelona, Espagne, 08028
- Fundacia ACE - Institut Catala de Neurociencies Aplicadas
-
Madrid, Espagne, 28040
- Hospital Clinico San Carlos
-
Madrid, Espagne, 28027
- Clinica Universidad de Navarra
-
Pamplona, Espagne, 31008
- Clinica Universidad de Navarra
-
Terrassa, Espagne, 08221
- Hospital Universitari MutuaTerrassa
-
Valencia, Espagne, 46017
- Centro Hospital Universitario Dr. Preset
-
-
-
-
-
Marseille, France, 13385
- Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
-
Montpellier, France, 43431
- Hopital Gui de Chauliac - CHRU de Montpellier
-
Paris, France, 75475
- Hopital Lariboisiere - Fernand-Widal - AP-HP
-
Rouen, France, 76031
- Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
-
Strasbourg, France, 67200
- Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
-
Toulouse, France, 31059
- Centre de Recherche Clinique du Gerontopole - CHU Toulouse
-
Villeurbanne, France, 69100
- Centre de Recherche-Hopital Geriatrique de Charpennes
-
-
-
-
-
Reykjavik, Islande, 101
- Memory Clinic, Landspitali University Hospital
-
-
-
-
-
's-Hertogenbosch, Pays-Bas, 5223 LA
- Brain Research Center Den Bosch
-
Amsterdam, Pays-Bas, 1081 GN
- Brain Research Center Amsterdam
-
Zwolle, Pays-Bas, 8025 AZ
- Brain Research Center Zwolle
-
-
-
-
-
Bristol, Royaume-Uni, BS32 4SY
- Re:Cognition Health Ltd Bristol
-
London, Royaume-Uni, EC2Y 8EA
- St. Pancras Clinical Research
-
Winchester, Royaume-Uni, SO21 1HU
- Re-Cognition Health Ltd Winchester
-
-
Devon
-
Plymouth, Devon, Royaume-Uni, PL6 8BT
- Re-Cognition Health Ltd Plymouth
-
-
Greater London
-
London, Greater London, Royaume-Uni, W1G 9JF
- Re-Cognition Health Ltd London
-
-
North Lanarkshire
-
Motherwell, North Lanarkshire, Royaume-Uni, ML1 4UF
- NeuroClin Glasgow Ltd
-
-
Surrey
-
Guildford, Surrey, Royaume-Uni, GU2 7YD
- Re-Cognition Health Ltd Guildford
-
-
West Midlands
-
Birmingham, West Midlands, Royaume-Uni, B16 8LT
- Re-Cognition Health Ltd Birmingham
-
-
-
-
-
Brno, Tchéquie, 656 91
- Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
-
Brno, Tchéquie, 602 00
- Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
-
Prague, Tchéquie, 160 00
- Neuropsychiatrie s.r.o.
-
Rychnov nad Kněžnou, Tchéquie, 51601
- Vestra Clinics - Dedicated Research Clinics
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85004
- Xenoscience
-
Scottsdale, Arizona, États-Unis, 85297
- CCT Research
-
Sun City, Arizona, États-Unis, 85351
- Banner Sun Health Research Institute
-
-
California
-
Costa Mesa, California, États-Unis, 92626
- ATP Clinical Research
-
Irvine, California, États-Unis, 92780
- Tilda Research
-
La Jolla, California, États-Unis, 92037
- UCSD Shiley-Marcos Alzheimer's Disease Research Center
-
Lomita, California, États-Unis, 90717
- Torrance Clinical Research Institute
-
Long Beach, California, États-Unis, 90806
- Collaborative NeuroScience Network LLC
-
Palo Alto, California, États-Unis, 94304
- Stanford University
-
Pasadena, California, États-Unis, 91105
- SC3 Research Group
-
Sacramento, California, États-Unis, 95816
- Sutter Health
-
-
Florida
-
Atlantis, Florida, États-Unis, 33462
- JEM Research Institute, Headlands Site
-
Bradenton, Florida, États-Unis, 34205
- Bradenton Research Center
-
Hialeah, Florida, États-Unis, 33016
- Galiz Research
-
Jupiter, Florida, États-Unis, 33458
- Alphab Global Research
-
Lady Lake, Florida, États-Unis, 32159
- Charter Research
-
Maitland, Florida, États-Unis, 32751
- K2 Medical Research, LLC
-
Miami, Florida, États-Unis, 33137
- Miami Jewish Health
-
Miami, Florida, États-Unis, 33144
- Y & L Advance Health Care, Inc /DBA Elite Clinical Research
-
Miami Beach, Florida, États-Unis, 33140
- Mount Sinai Medical Center
-
Naples, Florida, États-Unis, 34105
- Aqualane Clinical Research
-
Orlando, Florida, États-Unis, 32819
- Headlands Research Orlando
-
Orlando, Florida, États-Unis, 32803
- Charter Research
-
Palm Beach Gardens, Florida, États-Unis, 33410
- Advanced Research Consultants
-
Pompano Beach, Florida, États-Unis, 33064
- Quantum CNS Clinical Research
-
Port Orange, Florida, États-Unis, 32127
- Progressive Medical Research
-
Stuart, Florida, États-Unis, 34997
- ALZ Research and Treatment Center (A.R.T.C.)
-
Wellington, Florida, États-Unis, 33414
- ALZ Research and Treatment Center (A.R.T.C.)
-
West Palm Beach, Florida, États-Unis, 33407
- Premiere Research Institute
-
-
Georgia
-
Columbus, Georgia, États-Unis, 31909
- Columbus Memory Center
-
Decatur, Georgia, États-Unis, 30030
- Sandhill Research, LLC
-
-
Indiana
-
Fort Wayne, Indiana, États-Unis, 46804
- Fort Wayne Neurological Center
-
-
Louisiana
-
Shreveport, Louisiana, États-Unis, 71103
- Louisiana State University Health Sciences Center (LSUHSC)
-
-
Massachusetts
-
Plymouth, Massachusetts, États-Unis, 02360
- Headlands Research Eastern MA
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89106
- WR-CRCN
-
-
New Jersey
-
Toms River, New Jersey, États-Unis, 08755
- Advanced Memory Research Center
-
-
New York
-
Albany, New York, États-Unis, 12208
- Neurological Associates of Albany
-
New York, New York, États-Unis, 10016
- NYU Alzheimer's Disease Research Center
-
Orangeburg, New York, États-Unis, 10962
- Kline Institute for Psychiatric Research
-
Rochester, New York, États-Unis, 14620
- University of Rochester Medical Center
-
Staten Island, New York, États-Unis, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Greensboro, North Carolina, États-Unis, 27410
- Triad Clinical Trials
-
Matthews, North Carolina, États-Unis, 28105
- AMC Research
-
-
Ohio
-
Canton, Ohio, États-Unis, 44718
- NeuroScience Research Center
-
Dayton, Ohio, États-Unis, 45459
- Neurology Diagnostics, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73106
- IPS Research
-
-
Oregon
-
Portland, Oregon, États-Unis, 97225
- Center for Cognitive Health
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001
- Abington Neurological Associates
-
Allentown, Pennsylvania, États-Unis, 18104
- Lehigh Center for Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, États-Unis, 02914
- Rhode Island Mood & Memory Research Institute
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37212
- Vanderbilt Center for Cognitive Medicine
-
-
Texas
-
Houston, Texas, États-Unis, 77054
- UT Health Science Center at Houston
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Re:Cognition Health
-
-
Washington
-
Bellevue, Washington, États-Unis, 98007
- Northwest Clinical Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
- Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
- MMSE score at Screening of 22 to 30 (inclusive).
- CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
- RBANS delayed memory index score ≤ 85.
- Evidence of progressive memory loss over the last 12 months per investigator assessment
Exclusion Criteria:
- Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
- Diagnosis of neurodegenerative disorder other than AD.
- Diagnosis of major depressive disorder (MDD) within one year prior to screening.
- Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
- History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
- History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
- Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: ALZ-801
ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID). |
ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
Autres noms:
Placebo tablet BID |
|
Comparateur placebo: Placebo
Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study |
Placebo tablet BID |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
Délai: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
Délai: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal. |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Key Secondary Endpoint (A-IADL-W)
Délai: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
Key Secondary Endpoint (CDR-SB)
Délai: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD)
Délai: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE)
Délai: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Imaging Biomarker Endpoint (Hippocampal Volume)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Whole Brain Volume)
Délai: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Ventricular Volume)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
Délai: Baseline to Week 78
|
Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
Délai: Baseline to Week 78
|
Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
Délai: Baseline to Week 78
|
Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
A-IADL-W - MCI Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
A-IADL-W - Mild AD Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
CDR-SB - MCI Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
CDR-SB - Mild AD Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - MCI Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Mild AD Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE) - MCI Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE) - Mild AD Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
|
Hippocampal Volume (MCI Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Hippocampal Volume (Mild AD Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Whole Cortex) (MCI Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Mayo Index) (MCI Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex. |
Baseline to Week 78
|
|
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex. |
Baseline to Week 78
|
|
Whole Brain Volume (MCI Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Whole Brain Volume (Mild AD Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Ventricular Volume (MCI Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Ventricular Volume (Mild AD Subgroup)
Délai: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
Délai: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
Délai: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
A-IADL-W - Female Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
A-IADL-W - Male Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
CDR-SB - Female Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
CDR-SB - Male Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Female Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Male Subgroup
Délai: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Treatment Emergent Adverse Events (TEAE) - Females
Délai: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
|
Treatment Emergent Adverse Events (TEAE) - Males
Délai: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Susan Abushakra, MD, Alzheon Inc.
Publications et liens utiles
Publications générales
- Hey JA, Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada M, Doraiswamy PM, Elahi FM, Rissman RA, Liang E, Flint S, Hristova E, Kesslak P, McLaine R, Albayrak A, Schaefer JF, Yu JY, Tolar L, Tolar M. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes. Drugs. 2026 Sep 1. doi: 10.1007/s40265-026-02381-3. Online ahead of print.
- Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M. Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEepsilon4/epsilon4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ALZ-801-AD301
- R01AG065253 (Subvention/contrat des NIH des États-Unis)
- 2020-005755-20 (Numéro EudraCT)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .